Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More
The BSE stock has seen a breakout of falling resistance trendline adjoining March 15 last year (record high) and August 24 this year. The stock climbed over 6 percent to Rs 967.8 and formed long bullish candlestick pattern on the daily timeframe with above average volumes.
Poly Medicure rose 5 percent to Rs 952.5 and formed big bullish candlestick pattern on the daily charts with strong volumes. In fact, it has seen a breakout of downward sloping resistance trend line adjoining several points from the October high.
Sun Pharmaceutical’s foray into specialty drugs was in some ways driven by an existential threat posed by rising competition to its generic drug business in the US. In the September quarter, it reported sales of $200 million from specialty drugs in the US, up 27.5 percent YoY
The paper stocks were buzzing last week as we witnessed buying interest in some of the counters with good volumes. Satia Industries has seen a breakout from a long consolidation phase and has resumed its uptrend with a ‘Higher Top Higher Bottom’ structure
SPARC has witnessed a consolidation breakout on the back of robust volumes and surged above all its major EMAs (exponential moving averages) on the daily time frame. Simultaneously, in the last couple of sessions, strong traction has been seen in the overall sector.
Hot Stocks | On the downside, budget day's low of 17,244 will act as a sacrosanct support level. Below this, we can expect any weakness towards 17,000-16,800 levels, says Santosh Meena of Swastika Investmart.
Trade Spotlight | Here's what Rajesh Palviya of Axis Securities recommends investors should do with these stocks when the market resumes trading today
The long-term 200-DMA levels of 11,130 is going to act as a crucial support area for the Nifty. On the upside, resistance is seen around the 11,400 zone.
If Nifty fails to regain 11,720 in the coming week, it may trigger further selling pressure. Important support for Nifty is seen around the 11,500.
Sudarshan Sukhani of s2analytics.com advises buying ICICI Bank with a stoploss of Rs 355 and target of Rs 368.
In absence of any major cues, Indian market will be dependent on global cues this week as well as the movement of rupee against the US Dollar.
Most experts feel that the bull run remains intact but advise traders to remain cautious as the Nifty approaches crucial resistance levels of 11,900-12,000.
Prakash Gaba of prakashgaba.com suggests buying India Cements with target at Rs 133 and stop loss at Rs 124, ITC with target at Rs 325 and stop loss at Rs 315 and Sun Pharma Advanced with target at Rs 425 and stop loss at Rs 390.
HCL Tech, Bharat Forge, Sun Pharma and financials sector are being tracked by investors on Wednesday.
Ashwani Gujral of ashwanigujral.com recommends buying Blue Star, Sun Pharma and LIC Housing Finance.
Ashwani Gujral of ashwanigujral.com recommends buying Bombay Burmah, Karnataka Bank and Radico Khaitan.
Marico, NTPC, and Sun Pharma, among others, are being tracked by investors on Thursday.
Ashwani Gujral of ashwanigujral.com advises buying Aurobindo Pharma, Voltas and Sun Pharmaceutical Advanced Research Company.
Ashwani Gujral of ashwanigujral.com is of the view that one may buy PC Jeweller with a target at Rs 458.
Mitessh Thakkar of miteshthacker.com advises buying Aurobindo Pharma with a target of Rs 710.
According to Mitessh Thakkar of miteshthacker.com, one may buy SPARC and Aurobindo Pharma.
Ashwani Gujral of ashwanigujral.com is of the view that one can sell IRB Infra and UltraTech Cement and can buy Sun Pharma Advanced Research Company.
Mitessh Thakkar of miteshthacker.com recommends buying Bajaj Finserv and NCC.
Ashwani Gujral of ashwanigujral.com suggests buying Simplex Infra, NCC and United Spirits.
Ashwani Gujral of ashwanigujral.com has a buy on Rain Industries with a stop loss of Rs 315, target of Rs 332, a buy on United Breweries with a stop loss of Rs 1090, target of Rs 1150 and a buy on Sun Pharma Advanced Research with a stop loss of Rs 410, target of Rs 435.